Cuprina Holdings is offering 4,322,489 Class A ordinary shares at $1.15 each, with the issuer selling the shares and retaining the net proceeds. The Capital is intended for supply-chain expansion, Marketing and promotion, and working capital, while investors face a public price below the September 15 Nasdaq closing price.

Key Highlights

  • Cuprina Holdings is offering 4,322,489 Class A ordinary shares at $1.15 per share.
  • The underwriters have an option to purchase 648,373 additional Class A ordinary shares.
  • Cuprina currently intends to use net proceeds for supply-chain expansion, marketing and promotion, and working capital.

Cuprina Holdings (Cayman) LTD (NASDAQ: CUPR) is offering 4,322,489 Class A ordinary shares at $1.15 per share. The company’s Class A ordinary shares are listed on Nasdaq under the symbol CUPR. The public offering price is below the September 15 Nasdaq closing price of $2.93 for Cuprina’s Class A ordinary shares. The offering is being conducted on a firm commitment basis.

4.32M Shares Priced

The securities carry a Par Value of US$0.008 per Class A ordinary share. R. F. Lafferty & Co. Inc. is serving as the underwriter for the transaction. The underwriter also has an option to purchase 648,373 additional Class A ordinary shares. The offering size of 4,322,489 shares excludes any exercise of that additional-share option. The public price was set through discussions between Cuprina and R. F. Lafferty.

$1.15 Offering Price

Cuprina’s Class A ordinary shares were priced at $1.15 each. The prospectus says the price may be below the prevailing Market Price of the shares. The prospectus also says recent market prices may not indicate the actual public offering price. The issuer expects to receive net proceeds after Underwriting discounts and estimated offering expenses.

Stated Use of Proceeds

The company is a Singapore-based biomedical and biotechnology Business focused on products for chronic wound management and activities in the health and beauty sector. Its commercial products include medical-grade sterile blowfly larvae bio-dressings marketed under the MEDIFLY brand. Cuprina also identifies collagen dressings, iodine-based topical antiseptic products and products using medical leeches as pipeline chronic wound-care products. Development of those product lines is expected to take place during 2026 and 2027, subject to regulatory approval.

Nasdaq Listing

Each Class A ordinary share carries one vote, while each Class B ordinary share carries 100 votes and can be converted into one Class A ordinary share at the holder’s option. The company states that it currently intends to use net proceeds for supply-chain expansion, marketing and promotion, and working capital.